INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
MREONEW YORK, Aug. 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2
MREOBURLINGAME, Calif.--(BUSINESS WIRE)--āshibio, a privately held, clinical-stage biotechnology company developing novel therapeutics for the treatment of bone and connective tissue disorders, today announced an exclusive licensing agreement with Mereo BioPharma (NASDAQ: MREO) for vantictumab for the treatment of autosomal dominant osteopetrosis type 2 (ADO2), a rare, debilitating bone disorder with no approved therapies. The licensing of vantictumab represents a strategic expansion of āshibio’s p
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Mereo BioPharma Group plc - MREO
MREONEW YORK, Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Mereo BioPharma Group plc ("Mereo" or the "Company") (NASDAQ: MREO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The...
Needham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
MREOCORRECTION: Mereo BioPharma Q1 GAAP EPS $(0.02) Misses $(0.01) Estimate. Cash And Equivalents Of $62.5M
MREOMereo BioPharma Group Q1 EPS $(0.02) Beats $(0.54) Estimate
MREONeedham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
MREOJP Morgan Initiates Coverage On Mereo BioPharma Group with Overweight Rating, Announces Price Target of $7
MREONeedham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
MREOMereo BioPharma Group Q4 2024 GAAP EPS $(0.06) Beats $(1.03) Estimate
MREOCantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
MREONeedham Reiterates Buy on Mereo BioPharma Group, Maintains $7 Price Target
MREOReported Sunday, Mereo BioPharma Reports Progress In Setrusumab Phase 3 Study For OI And Awaits EMA Decision On Alvelestat Orphan Designation
MREOThis ServiceNow Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday
MREOLifeSci Capital Initiates Coverage On Mereo BioPharma Group with Outperform Rating, Announces Price Target of $10
MREOCantor Fitzgerald Reiterates Overweight on Mereo BioPharma Group, Maintains $7 Price Target
MREONeedham Reiterates Buy on Mereo BioPharma Group, Maintains $6 Price Target
MREOMereo BioPharma Provides Clinical Update And Interim Biomarker Analysis Presented At ESMO 2022 From ACTIVATE Phase 1b/2 Open Label Study Of Etigilimab
MREO